Summary Five samples of tonsil, 10 reactive lymph nodes and 65 consecutive cases of non-Hodgkin lymphoma (NHL) were evaluated in suspension phenotyping with the monoclonal antibodies aLeu-I, aLeu-2a, aLeu-3a, OKT1, OKT3, OKT4, OKT6, OKT8, W6/32, 26/114, DA-2, 2DI, J5, AN51 and OKT9 together with conventional surface marking by rosetting (E, Fcy, Fcts, C3b, C3d) Previous reports on phenotyping in non Hodgkin's lymphoma (NHL) indicate marked heterogeneity within tumours of similar appearance and histological class. Nevertheless such studies have shown broad correlation between histological class and phenotype (Jaffe et al., 1974; Gajl-Peczalska et al., 1975; Stein, 1976; Stathopoulos et al., 1977; Brouet, et al., 1977; Jaffe et al., 1977; Lukes et al., 1978; Stein et al., 1979; Habeshaw et al., 1979; Janossy et al., 1980; Aisenberg, 1981) A significant effect of these studies has been to focus attention on the cellular origin, differentiation and possible pathogenic role of the cell populations within the lesions. This applies particularly to the T cell populations accompanying B lymphocytic neoplasia of follicular and immunoblastic types (Habeshaw et al., 1979; Janossy et al., 1980) , which until recently were evaluable only on the basis of E rosette formation, or reactivity with heteroantisera of pan T cell or limited T cell subset specificity (Evans et al., 1978 
Summary Five samples of tonsil, 10 reactive lymph nodes and 65 consecutive cases of non-Hodgkin lymphoma (NHL) were evaluated in suspension phenotyping with the monoclonal antibodies aLeu-I, aLeu-2a, aLeu-3a, OKT1, OKT3, OKT4, OKT6, OKT8, W6/32, 26/114, DA-2, 2DI, J5, AN51 and OKT9 together with conventional surface marking by rosetting (E, Fcy, Fcts, C3b, C3d) and staining for surface and cytoplasmic immunoglobulin (Slg, CyIg) heavy and light chain classes. The results confirm the reproductability and specificity of staining with monoclonal antibodies against T cells and T cells subsets. Evidence is presented for reactivity of aLeu-I antibody with SIg positive and Ia positive cells in some lymphomas (centroblastic centrocytic, lymphocytic and immunoblastic), and 2 cases showed evidence of marking with OKT3 on SIg positive cells in T cell predominant immunoblastic lymphoma. Lymphoblastic lymphomas of T cell type expressed the marker OKT6. On the basis of these results criteria for the diagnosis of T cell lymphoma are suggested. The monoclonal antibody J5, reactive with C-ALL antigen, showed variable positivity, occasionally strong in B cells in cases of centroblastic and centrocytic follicular lymphoma. Proportions of cells staining with the monoclonal antibody OKT9 showed a correlation between levels of cellular expression of transferrin (trf) receptor and the histological grade of malignancy, OKT9' cells being elevated in high grade lymphomas, and in some cases of transforming lymphoma of low grade histological class. These results are discussed and indicate the advantage of employing a wide range of defined monoclonal reagents in the phenotypic evaluation of NHL.
Previous reports on phenotyping in non Hodgkin's lymphoma (NHL) indicate marked heterogeneity within tumours of similar appearance and histological class. Nevertheless such studies have shown broad correlation between histological class and phenotype (Jaffe et al., 1974; Gajl-Peczalska et al., 1975; Stein, 1976; Stathopoulos et al., 1977; Brouet, et al., 1977; Jaffe et al., 1977; Lukes et al., 1978; Stein et al., 1979; Habeshaw et al., 1979; Janossy et al., 1980; Aisenberg, 1981) , although it is not yet clear what contribution more precise immunological diagnosis can make to the management of this disease (Bloomfield et al., 1979; Strauchan et al., 1978) . A significant effect of these studies has been to focus attention on the cellular origin, differentiation and possible pathogenic role of the cell populations within the lesions. This applies particularly to the T cell populations accompanying B lymphocytic neoplasia of follicular and immunoblastic types (Habeshaw et al., 1979; Janossy et al., 1980) , which until recently were evaluable only on the basis of E rosette formation, or reactivity with heteroantisera of pan T cell or limited T cell subset specificity (Evans et al., 1978) . With the availability of Correspondence: J.A. Habeshaw. Received 27 September 1982;  accepted 23 November 1982. monoclonal antibodies, it is now possible to accurately quantify functionally correlated T cell subsets (Reinherz et al., 1980b) within the lesions in both suspensions and frozen sections. Since many of these reagents are currently available commercially, we have attempted to evaluate their utility in phenotyping normal and neoplastic lymphoid tissues.
In this paper we report the results of a phenotypic analysis of 10 reactive lymph nodes and 65 consecutive cases of NHL studied with a range of monoclonal antibodies of pan T cell and T cell subset specificity, other monoclonals of defined specificity for lymphoid cell surface antigens, andlymphomas of mature T lineage cells and (d) characterise cells previously described in tumours as "null" or "receptor silent" with "conventional" modes of surface phenotyping.
Patients
Patients attended the Medical Oncology Unit, St. Bartholomew's Hospital, from January 1981 to December 1981. (Adult patients were under the care of Dr T.A. Lister, and children under that of Professor J.S. Malpas).
Materials and methods

Lymph nodes and tissues: cell suspensions
Single cell suspensions from lymph node biopsies were prepared in tissue culture medium RPMI 1640 within 20min of surgical removal. Peripheral blood and splenic lymphocytes were prepared by centrifugation on Lymphoprep (Nygaard) at 400g for 25min at 200C. Pleural aspirates were diluted with tissue culture medium RPMI 1640 containing heparin (10 unitsml-1) and the cells recovered after washing and centrifugation. Cell counts were adjusted to give a concentration of 5x 106 nucleated cells ml-1 and viability was assessed by trypan blue dye exclusion.
Preparation of red cells
Sensitised red cells for assessment of Fcy, Fc/u, C3d receptors were prepared as previously described (Habeshaw et al., 1979) . C3b-sensitised ox RBC were prepared using R3 reagent incubated with IGM-sensitised ox RBC for 75 sec at 37°C, followed by dilution and washing with ice-cold veronal buffered saline at 0°C. Cells sensitised in this manner are equivalent in their reactivity with C3b receptor expressing cell lines as red cells prepared with purified C components known to express human C3b.
Preparation and use of antibodies for suspension phenotyping For the detection of surface Ig on untreated or acetate washed lymphoid cells in suspension, conventional, commercially available rabbit or goat antisera, or FITC conjugates of IgG preparations, were used. These included antisera against i, y, and a heavy chains, K and A light chains (Nordic, Miles, Dako, Behringwerke) . Purified IgG fractions were prepared from whole antiserum by ammonium sulphate precipitation, DEAE sephadex chromatography, or affinity chromatography on staph protein A-Sepharose (Pharmacia). Two preparations of anti-IgD antiserum were used, goat anti-human IgD (courtesy of G. Janossy and S. Mattingley, Royal Free Hospital) and sheep antihuman IgD (Seward Laboratories). y-globulin fractions prepared from these antisera were absorbed against CNBR-sepharose coupled human IgG and conjugated with FITC by the method of Forni (1979) to give a final product containing 0.25mgml-1 antibody and F:P ratio of 2:1 to 4:1. These antisera were diluted to 1:10-1:16, aliquoted in 10ul quantities and used at a final dilution of 1:20. All antisera were deaggregated by centrifugation (1O0,000 g for 1 h) before use.
Monoclonal antibodies
The monoclonal antibodies (obtained from commercial sources, or from other laboratories) used in this study are given in the Appendix. They were tested for reactivity against a range of normal lymphocytes from tonsil, blood and lymph nodes, and against CLL or ALL cells where appropriate. Effective dilutions were established empirically for these reagents, which were then aliquoted in 5 jpl quantities and stored as recommended by the manufacturers (at + 4°C or below -4°C). The effective antibody concentrations used were from 100-250 ,g ml-1 antibody protein and reagents at this concentration were used at final dilutions of 1:15-1:25.
Binding of monoclonal antibodies was detected using goat anti-mouse (GAM) Ig obtained by affinity chromatography of whole goat anti-mouse serum on mouse IgG columns. The retained and eluted Ig was then passed through a column of Sepharose coupled pooled human Ig (IgG and IgM) to remove any cross-reactivity with human Ig. The GAM IgG was coupled with fluorescein isothiocyanate (Sigma) by the method of Forni (1979) to give a product containing 0.38mg ml-l IgG, with an F:P ratio of 3:1. This preparation was diluted 1:25, aliquoted in 5 ul quantities, and used at a final dilution of 1:10. Control incubations indicated no detectable reactivity with human leukocyte preparations at the dilutions used.
Peanut lectin staining FITC-conjugated PNA was prepared according to the method described in Rose et al. (1980) .
Phenotypic analysis
The methods of quantitating E rosettes, Fcy, Fc,u, C3b and C3d rosettes, SIg and CyIg staining were as previously described (Habeshaw et al., 1979) . (Table I ) and lymph nodes (Table II) . There were no significant differences in the proportions of T cells determined by aLeu-I and OKT3 pan T cell antibodies, or between the subset specific monoclonals OKT4/ocLeu-3a and OKT8/cLeu-2a.
The T cell subset ratios with these pairs of antibodies were not significantly different.
The anatomical distribution of the T cell subsets defined by these monoclonals and B cell types defined by conventional antisera and HLA-Dr specific monoclonals are given in Table III (data for W6/32, J5 and OKT6 not shown).
(data for Fc,u and PNA not shown). (Reinherz et al., 1979a (Reinherz et al., , b, 1980b Janossy et al., 1980; Poppema et al., 1981) . In view of these data, T cell subset-specific monoclonals OKTl/aLeu-I, OKT3/UCHT-I, and the T cell marker E rosettes, are expressed separately, and T cell proportions assessed as defined below.
The total numbers of T cells in a given sample of normal or malignant peripheral lymphoid tissue are equivalent to the population defined by the pan T cell monoclonals OKT3 and UCHT-I. The cytotoxic/suppressor subset is defined as the (Leu- Six cases of centrocytic lymphoma (Table IX) showed a B cell predominant phenotype, with low levels of total T cells. In patients A.C. and G.Co., Leu-I (Izaguirre, 1982 In view of the data from surface phenotyping of immunoblastic lymphoma and follicular lymphoma, the status of the entity "T cell immunoblastic" lymphoma is not clear. T cell predominance in a monoclonal B cell tumour, in which the T cells have undergone blast transformation, or in which a B cell subset expresses acquired or dysfunctional OKT3 markers, is superficially a "T" cell lymphoma (at least on histological criteria). It is important to recognise that although in immunoblastic lymphoma the blast-transformed population marks as "T" lymphoid, there may be phenotypic evidence of an additional, cell population. non-transformed "monoclonal" B Malignant lymphocytic lymphoma The profiles of involved tissues of 10 patients with malignant lymphocytic lymphoma, and CLL, are given in Table XI The antigenic markers of T lineage specificity considered are E rosette (or OKT1 la) positivity, OKT3/UCHT-I, OKT4/aLeu-3a, OKT8/aLeu-2a Table XII . An additional case of "T" lymphoma diagnosed on histology/cytology but not fulfilling all these criteria is also shown here (Patient R.E.).
The patients A.S., F.S., E.M., P.J., C.M. (Table  XII) with adult "T cell" lymphoma showed T cell predominance in the affected tissues, of a single defined T cell subset. In patient F.S., with classical T zone lymphoma involving lymph node paracortex, this T cell population was phenotypically E +, Leu-I +, OKT3 + and essentially OKT4/Leu-3a-, OKT8/Leu-2a-. In patient A.S., with Sezary cell leukaemia, the phenotype was EB Leu-I+ OKT4+ OKT8+, with strong suggestion of overlap of these markers on the affected population. In patient C.M., with T cell PLL, the major population was E + Leu-I + OKT3 + with a high proportion of OKT9+ cells.
Patient E.M. had Sezary cell leukaemia supervening in long-standing mycosis fungoides. The lymph node showed E +, aLeu-I +, OKT3 +, UCHT-I +, OKT4+ and aLeu-3a + to be the phenotype of the major cell population. More All populations in patient R.E. expressed HLA-ABC and were 2DI , suggesting a lymphoid or haematopoetic origin for the neoplastic cells, and in both node biopsies, OKT9 staining was detectable on the entire lymphoid population. Although the significance of this finding is obscure, it might indicate similarity with previously described cases where T cell markers were expressed (Kung et al., 1981; Aisenberg & Wilkes, 1980) .
Lymphoblastic lymphoma of Tcell or null cell type
The phenotype of ALL shows 3 major subclasses of disease: T cell type, C-ALL type, and B cell type. These sub-groups correspond histologically to the lymphoblastic lymphomas of childhood, which on morphological and cytochemical criteria can be segregated into T lymphoblastic lymphoma, unclassified lymphoblastic lymphoma (U) and lymphoblastic lymphoma of "Burkitt" type (B lymphoblastic lymphoma).
In the histological categories of T lymphoblastic and U lymphoblastic lymphoma, previous studies have indicated phenotypic similarities between the lymphoma and the corresponding cytological type of acute leukaemia; it is currently not clear whether the acute leukaemias are separate entities, or whether lymphoblastic lymphomas are variants of ALL (Habeshaw, 1981; Coccia, 1977; Murphy, 1978) . In table XIII the phenotypic data are presented for one control thymus gland (C.W.), 6 cases of lymphoblastic lymphoma thought to be T cell type on histological and cytological criteria (patients J.P.C., K.F., A.N., S.B., J.P., J.C.) and 2 patients with lymphoblastic lymphoma of U cell type (patients L.T., Y.K. 
Discussion
Monoclonal antibodies represent molecular probes which allow the detection of a single kind of antigenic structure upon the cell surface. The use of these reagents to classify cell subpopulations provides a practical means of defining the cellular composition of malignant lymphoma. The findings reported here, and previously published data on the specificity of monoclonal reagents (Reinherz et al., 1979a, b; and on the distribution of the identified cell subsets in tissues (Janossy et al., 1980; Poppema et al., 1981) support the contention that T cell-specific monoclonal antibodies used in NHL consistently and reproducably define cell subsets (Table VIII) ), centrocytic small cell lymphoma (patients P.C. and G.C. (Table IX) ); immunoblastic lymphoma (patients J.B., J.N., F.B. (Table XII) ). Leu-I+ B cells do also occur as a normal lymphoid cell subset (Caligaris-Cappio et al., 1982) . 2 The OKT3/UCHT-I defined 19K MW glycoprotein antigen found mainly on peripheral T cell subsets, but which can occur separately from either Leu-I or the "helper/suppressor" subset antigens (see patients C.B. (Table VII) , R.N. (Table VIII) , G.S. and J.E. (Table X) ). 3 The OKT4/ocLeu-3a defined antigen found on T cell subsets with helper/inducer activity which occurs reciprocally with a second antigen OKT8/Leu-2a expressed by T cell subsets with cytotoxic activity. Occasionally both antigens may appear together on the same cell (patient A.S. (Table XII) ), particularly in thymus gland (J.W. (Table XIV) ) or in T lymphoblastic lymphoma (Patient A.N. (Table XIV) ). 4 The OKT8/aLeu-2a defined antigen confined to cytotoxic/suppressor T cell populations, which are found in thymus or T lymphoblastic lymphoma, or as a constituent of reactive nodes. No peripheral T cell malignancy of suppressor/cytotoxic subclass was found in this series, although reversed ratios of "helper/inducer:cytotoxic/suppressor" T cells were common in the described cases. 5 The receptor for sheep erythrocytes behaves as a separate T cell specific marker, and is quite often not represented on defined T cell populations of either helper/inducer or cytotoxic/suppressor subclasses (e.g. patients P.A., M.E., E.B. (Table  VIII) ). The antigen detected by OKTI1 or OKTlla monoclonals shows similar distribution to the SRBC "receptor" (Verbi et al., 1982) . 6 The thymic cortical antigen defined by OKT6, present only in thymus gland or T lymphoblastic lymphoma. Although never found on lymphoid populations in reactive tissues, OKT6 expression can occur on Langerhans cells in skin, and in the sinuses of peripheral lymph nodes.
Since direct-coupled (FITC-or TRITC-labelled) monoclonals were not available for this study it was not practicable to test the simultaneous expression of 2 different antigens on one cell, therefore the existence of further heterogeneity of T cells in lymphoma beyond that described here cannot be excluded.
Other monoclonal reagents M/32 The monoclonal antibodies W6/32 (anti HLA-ABC) and DA-2 (anti HLA-DR) have appreciable value for phenotyping in suspension. W6/32 does not react with red cells, but reacts with all nucleated cells, including plasma cells, monocytes/macrophages, and epithelial cells. In thymus, W6/32 negative cells occur, and the presence of these cells bears an important relationship to the expression of aLeu-I defined antigen, OKT6-defined antigen and expression of PNA binding.
DA-2 The monoclonal DA-2 against HLA-DR is expressed by most B cells (but not by plasma cells) and in frozen section is also found to be strongly expressed by the inter-digitating reticulum cell of the T cell areas. Other HLA-DR positive cell classes include C-ALL antigen positive cells and blast transformed T4/Leu-3a' T cells (Janossy et al., 1977; Reinherz et al., 1979c) . J5 The J5 monoclonal, which detects the 95K C-ALL antigen, is found to bind to some B cells in lymphomas, particularly of the follicular CB/cc subclass in suspension. J5 also reacted with a cell sub-population in OKT6+ TdT+ T lymphoblastic lymphoma. This C-ALL antigen expression at low levels in T lymphoblastic lymphoma has previously been noted using rabbit anti-ALL antibody (Habeshaw, 1981) and is present in some T lymphoblastic cell lines (Minowada et al., 1978; Roberts et al., 1978; Greaves et al., 1981) . 2DI The monoclonal antibody 2DI has proved very useful in eliminating from the series "receptor silent" tumours of uncertain histogenesis. All lymphoid cell populations presented here were defined by 2DI positivity confirming the validity of this marker for "lymphoid" populations in general.
OKT9 expression in relation to histological class of lymphoma The monoclonal OKT9 did not act as a T lymphocyte specific marker. On the other hand, OKT9 expression was found to correlate with histological class of lymphoma as shown in Table   XV .
It may be that the levels of OKT9 positivity reflect the proliferative potential within any class of lymphoma, since as shown here, the high grade lymphomas tend to show higher levels of OKT9+ cells on average than low grade lymphoma (high grade > 10, low grade < 5). Since OKT9 detects the trf receptor, then rapidly growing cells, with a high metabolic demand for iron, may express receptors for trf in proportion to their rate of proliferation (Sutherland et al., 1981) . It is of further interest that a proportion of transforming B cell tumours express increased OKT 9 positivity, while T cell predominant transformation is not accompanied by increased OKT9 positivity.
Phenotypic heterogeneity of null cells
All the null cell populations described express HLA-ABC antigen and are found to be positive for HLeI by the monoclonal 2DI. "Null" cell populations occur frequently in lymphomas, and in reactive lymph nodes. The cell type marking as "null" has the phenotype HLA+ 2DI+ HLA-DR-, and does not appear to express Fcy, Fcji, C3b or C3d receptors. Lymphomas having significant null populations of this type are centroblastic centrocytic follicular (Patients A.S., P.A., R.N. (Table VIII) ), lymphocytic lymphoma (Patients E.H. (Table XII) ) and "T zone" lymphoma (patient R.E. (Table XIII) ). Null populations were not found in centrocytic lymphoma, centroblastic lymphoma, or immunoblastic lymphoma. Previous reports of "null" populations include E -T cells and Leu-I+ SIg-HLA-DR+cells, which can only be sub-classified using specific monoclonals. Failure to find CyIg, the absence of HLA-DR, and the apparent lack (or inconsistent expression) of Fcy and C3b receptors suggest the null cell is neither a plasma cell, nor a mononuclear phagocyte of conventional type. It is thought unlikely to be of B cell lineage, but could represent a subset of T lineage cells, not detectable with current markers. This is suggested from the existence of populations bearing only the T cell specific marker.
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In addition to the HLA-ABC+ 2DI+ HLA-DR-"null" cell, other cells are found which express only one class specific marker (other than SIg), These include the E+ cell with no expression of other T cell markers (HLA+ 2DI+ E+) and (Leu-I+ HLA-DR') phenotype. The former phenotype occurred in immunoblastic lymphoma (J.P. (Table X) ), centroblastic lymphoma (M.B. (Table VII) ) and lymphoblastic lymphoma (J.D. (Table XV) ). Leu-I+ cells of the phenotypes (HLA-ABC+ 2DI + Leu-I+ SIg + and/or HLA-DR +) were present in centroblastic and centrocytic follicular lymphoma (P.A. (Table VIII) ), centrocytic lymphoma of small cell type (patients P.C., J.E., J.M. (Table X) ) and lymphocytic lymphoma (Patients J.B., J.N. and F.B. (Table XII) ).
Phenotypic heterogeneity in peripheral Tcells
There is evidence from this series that the antigens detected by the monoclonals aLeu-I (OKTI), OKT6, OKT3/UCHT-I, OKT4/axLeu-3a or OKT8/aLeu-2a, and E rosette formation provide a number of separate T cell phenotypes dependent 346 J.A. HABESHAW et al. upon the independent expression of these antigens.
Thus, although, peripheral T cells are normally E+, OKT3/UCHT-I +, OKT4/Leu-3a+ or OKT8/Leu2a+, independent expression of these markers does occur, giving rise to E-, OKT3/UCHT-I +, OKT4/Leu-3a-, OKT8/Leu-2a-phenotypes within the cell series classified as "T". It was found that the T subset specific markers OKT4/aLeu-3a, OKT8/ocLeu-2a never occurred without expression of OKT3/UCHT-I and/or Leu-I. There is no evidence that expression of OKT3/UCHT-I antigen or Leu-I antigen is dependent on OKT4/Leu-3a, OKT8/Leu-2a antigen expression. E-T cell populations are common (E-OKT3/UCHT-I +), occurring with both OKT4/Leu-3a positive and OKT8/Leu-2a+ subclass specific markers. The monoclonal antibody OKT1 la, which detects the sheep erythrocyte receptor (Verbi et al., 1982) was not used in this series; the results obtained with E rosetting would also apply to this antibody. E-T cell populations were found in centroblastic lymphoma (patients I.C., J.S., C.B. (Table VII) ), in centroblastic/centrocytic follicular lymphoma (patients P.A., D.C., M.E., E.B. (Table VIII) ) and in patients with T cell lymphoma (E.M. (blood) and P.J. (Table XIII) ). In a number of other cases E rosette levels were somewhat below total T cell levels determined by pan T cell markers (e.g. patient D.L. (Table IX) ), probably due to the inherent variability of the rosette technique.
In 4 cases (Patient C.B., (Table 7) , R.N. (Table  VIII) , G.S. and J.E. (Table X) ) a significant proportion of the total T cells expressed the pan T cell markers ocLeu-I and/or OKT3/UCHT-I only. In these patients total T "helper" and "suppressor" T cells did not equal total T cells. The differences encountered were not great, but do suggest the presence of an undefined peripheral T cell with phenotype Leu-I+ OKT3/UCHT-I+ (E+), unreactive with OKT4/aLeu-3a or OKT8/aLeu-2a antibodies.
"Double marked" OKT4+ OKT8+ T cell populations have been described (e.g. in prolymphocytic leukaemia) and also occur in thymus gland (Greaves et al., 1981) . In this series, only one case (A.B. (CB/cc/F Table VIII)) showed clearly a double-marked T cell population.
Phenotypic heterogeneity of intrathymic Tcell subsets It is believed that the phenotypes described of T cell precursors and T cells of normal thymus gland, are analogous to those of lymphoblastic leukaemia of T cell type (Bhan et al., 1980; Greaves et al., 1981) .
In lymphoblastic lymphoma, homogeneous populations can be found (e.g. patient S.B. (Table   XIV In a recent paper, Bernard et al. (1981) reported a series of 21 patients with lymphoblastic lymphoma, and found phenotypic variants similar to those described here. Commonly T lymphoblastic lymphoma cells expressed T6 antigen with both OKT4 and OKT8 expressed, together with the thymocyte specific monoclonal OKT1O. Three patients in their series expressed J5 reactivity, and 2 patients expressed both OKT3 and OKT6 antigens.
The monoclonal A50 (Boumsell et al., 1980) Caligaris-Cappio et al., 1982) of peripheral origin and represent early "B memory" cells, the germinal centre B cell precursor may well prove to be a C-ALL+ SIg+ and HLA-DR+ B lineage cell-a significant B cell component of most follicular lymphomas. The presence of C-ALL antigen has been previously shown on some cases of B lymphoblastic lymphoma (Habeshaw, 1981) , and pre-B cells in C-ALL, and would suggest that the lymphoblastic lymphoma of B cell type in children, and CB/cc/F lymphoma in adults, may be clearly related in their ontogenesis, despite the contrasting histological appearances and clinical behaviour.
With the means to describe accurately the T cell populations in NHL, there is a temptation to regard deviations of T cell phenotype from the prescribed "T helper/inducer" or "T cytotoxic/suppressor" subsets as evidence of "neoplastic" transformation of T cells with or without B cells in lymphoma. In our opinion there is no evidence that unusual phenotypes (such as OKT4/OKT8 double-marking T cell populations) are necessarily "neoplastic" attributes of lymphoid cells. Nor is there evidence from the phenotype to suggest that proliferative B cell malignancies are caused by unopposed "T helper" cell function or are subject to ineffective "T suppression", as both types of cell are usually present in normal proportions. In normal or reactive nodes, the T cell component is of both major subclasses, is arranged in a similar distribution, and presumably has the same function as the T cell component in, for example, centroblastic and centrocytic follicular lymphoma. The excess of OKT8/Leu-2a+ T cells over OKT4/Leu-3a+ T cells commonly observed in this series is also observed, though less commonly, in reactive lymph nodes, but does not alone imply a reaction by "cytotoxic" T cells against "neoplastic" B cells. Moreover, there is good evidence that the clonogenic components of NHL B cells are, like normal B cells, dependent upon T cell factors, and T cells, for growth (Izaguirre et al., 1980) .
If abnormal (or "neoplastic") T cell phenotypes are to be found, they would presumably be most common in T cell lymphomas. Again, where this is observed, T cell lymphomas appear to have quite clearly developed attributes of T "helper" cells (Kung et al., 1981) , or phenotypes compatible with origins from within thymus gland (Bernard et al., 1981) .
However, a proportion of high grade lymphomas, histologically and cytologically defined as being of "T cell" type, include light chain class restricted B lymphoid components expressing surface and cytoplasmic Ig. Similarly, B cell immunoblastic lymphoma, of restricted L chain class, is often accompanied by a major population of active, and in some cases blast transformed HLA-DR + T lymphocytes in the lesion.
In this respect, previously published data (Habeshaw et al., 1979) indicate that repeat biopsies of T cell predominant lesions show T cell predominance to be merely one phase in the evolution of a dominant light chain class-restricted B cell population with apparent malignant potential. For understanding the nature of lymphoma it is important to establish whether the T cell predominance is associated with the normal immunoregulatory mechanisms of T cells upon B cells rather than concluding from the local predominance of one cell class that the neoplasm was essentially composed of "malignant" cells of that type. For this reason the phenotypic criteria adopted for defining a neoplasm as "T cell type" are stringent, and emphasise the necessity of looking for and excluding significant "monoclonal" B cell populations in the affected tissues.
Suspension phenotyping shows that most NHL are composed of mixtures of cells. These mixtures include T cells of both major subsets, and B cells which may show heterogeneity of heavy chain isotype, HLA-DR expression, markers such as C3b/C3d receptor expression, or PNA binding. Even T lymphoblastic lymphomas show some evidence of being composed of mixtures of phenotypically distinct subsets of cells, which may mimic the normal patterns of phenotypic variation occurring during intrathymic differentiation. The T cell component in Hodgkin's Disease (Dorreen et al., 1982) or in follicular lymphoma is often not demonstrably abnormal in respect of the relative proportions of T "helper" or "suppressor" cells, or in their distribution as assessed by frozen section. Nonetheless, mixtures of such cells do, in individual patients, show the capacity for progressive growth, ultimately with the emergence of a dominant B cell population showing light chain class restriction, and probably derived from a single B cell clone. From these observations, it is proposed that T cell populations in NHL of "B" cell type are an integral part of the proliferative process, acting in the selection and stimulation of the B cell component in a manner analogous to the normal immune response. The presence of a progressive, and ultimately fatal, lymphoid proliferation represents a rather gross disturbance of normal function which is not always reflected in the cellular composition of the neoplasm itself. This observation suggests that the presence of a lymphoid neoplasm may be symptomatic of a more widespread constitutional disturbance of lymphoid homeostasis affecting the immune system as a whole, rather than being the expression of an intrinsic "malignant" attribute of a single B cell clone. In view of the reported recent success in the treatment of a lymphoma by monoclonal anti-idiotypic antibody (Miller et al., 1982) , defective immunoregulation at this level might well prove to be a major factor in the pathogenesis of lymphoid neoplasia.
acLeu-2a Clone SKI, an IgG antibody defining an antigen complex of 2 or more disulphide bonded subunits of 32K and 43K MW. Present on a subset of T lymphocytes responsible for cell-mediated lymphosis (suppress or/cytotoxic subset) (Ledbetter et al., 1981) .
aLeu-3a Clone SK3, an IgGI antibody defining a 55K MW antigen present upon T cells mediating PWM-induced B cell antibody synthesis (Evans et al., 1981) .
OKT1 An IgGI antibody reacting with 70K MW antigen expressed on all peripheral T cells and a subpopulation of thymocytes (Reinherz et al., 1979 ) . P17/F12 and TIOI react with the same antigen (Engleman & Levy, 1980) . OKT3 Monoclonal IgG2a antibody reacting with a 19K MW antigen expressed on all peripheral T cells, including both suppressor/cytotoxic and helper/inducer subclasses (Kung et al., 1979) . OKT4 Monoclonal IgG2b antibody reactive with a 62K MW antigen present on human T cells of helper/inducer subclass (TH2 T cells) (Kung et al., 1979; Reinherz et al., 1979a,b) . OKT6 Monoclonal IgG antibody reactive with a 49K MW antigen expressed only on thymocytes, and absent from peripheral T cells (Reinherz et al., 1980a) . Similar monoclonal is Nal/34 (McMichael et al., 1979) .
OKT8 Monoclonal IgG2a antibody reactive with an undefined antigen of peripheral T cells of cytotoxic/suppressor subclass (TH2 +) (Reinherz et al., 1980b) . A similar but not identical antibody is OKT5 (Reinherz et al., 1980b) .
W6/32 Monoclonal IgG2a antibody reactive with the 43K glycoprotein "core" chain of HLA A, B, (C) antigens (Trucco et al., 1979) .
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DA-2 Monoclonal IgG2a antibody directed against polymorphic p28/33 glycoprotein "core" structure of HLA-DR determinants (Brodsky et al., 1979) . 2DI Monoclonal IgGI antibody directed against a human haematopoietic cell antigen (HLeI) of 70K MW, present on lymphoid and myeloid cells, weakly expressed on granulocytes, monocytes and early erythroid precursors. Absent from a wide variety of tested epithelia (Beverly et al., 1980) . J5 Monoclonal mouse IgG2a antibody reactive with the 95K antigen of C-ALL cells (Ritz et al., 1980) . AN51 Monoclonal antibody reactive with human platelet glycoprotein I. Unreactive with human lymphoid cells (McMichael et al., 1981) .
OKT9 Monoclonal antibody reactive with an 80K dimeric antigen expressed on thymic T cell (Reinherz et al., 1 980a) . It is now known to be reactive with the cellular receptor for trf (Sutherland et al., 1981) 
